Validation of a novel patient reported tool to assess the impact of treatment in erythropoietic protoporphyria: the EPP-QoL
Abstract Background A novel treatment has been developed for erythropoietic protoporphyria (EPP) (a rare condition that leaves patients highly sensitive to light). To fully understand the burden of EPP and the benefit of treatment, a novel patient reported outcome (PRO) measure was developed called...
Main Authors: | G. Biolcatti, S. Hanneken, E. I. Minder, N. J. Neumann, J. H. P. Wilson, P. J. Wolgen, D. J. Wright, A. J. Lloyd |
---|---|
Format: | Article |
Language: | English |
Published: |
SpringerOpen
2021-08-01
|
Series: | Journal of Patient-Reported Outcomes |
Subjects: | |
Online Access: | https://doi.org/10.1186/s41687-021-00345-7 |
Similar Items
-
Surgical treatment for breast cancer in a patient with erythropoietic protoporphyria and photosensitivity: a case report
by: Akiko Shimazaki, et al.
Published: (2021-01-01) -
Erythropoietic Protoporphyria in a Japanese Population
by: Megumi Mizawa, et al.
Published: (2019-04-01) -
The 6-year follow-up of a Japanese patient with silent erythropoietic protoporphyria
by: Megumi Mizawa, MD, PhD, et al.
Published: (2017-05-01) -
Illuminating Dersimelagon: A Novel Agent in the Treatment of Erythropoietic Protoporphyria and X-Linked Protoporphyria
by: Katelyn E. Madigan, et al.
Published: (2023-12-01) -
Diagnosis and treatment of icteric hepatitis caused by erythropoietic protoporphyria: A case report
by: Hanqing Huang, et al.
Published: (2022-06-01)